Loading...
•
Sep 30, 2024
ImmunityBio Q3 2024 Earnings Report
Reported financial results for the third-quarter ended September 30, 2024.
Key Takeaways
ImmunityBio reported a net product revenue of approximately $6.0 million during the three months ended September 30, 2024, surpassing net product revenue of $1.0 million in the prior quarter and analyst estimates. The company's cash and marketable securities position was $130.4 million as of September 30, 2024.
ANKTIVA received a J-code (HCPCS Level II Code) in October 2024, effective January 1, 2025.
ANKTIVA is now widely accessible to patients through commercial and government insurance programs, securing coverage for over 200 million medical lives.
Net product revenue reached approximately $6.0 million during the three months ended September 30, 2024, exceeding the previous quarter and analyst estimates.
The company has extended the shelf life of ANKTIVA from two years to three years, with over 125,000 doses available.
ImmunityBio
ImmunityBio
ImmunityBio Revenue by Segment
Revenue by Segment
Product revenue, net Revenue
CapyFin.comOther revenues Revenue
CapyFin.com Forward Guidance
The company anticipates an EU submission this quarter.
Revenue & Expenses
Visualization of income flow from segment revenue to net income